147 related articles for article (PubMed ID: 24265090)
1. Does genotyping of risk-associated single nucleotide polymorphisms improve patient selection for prostate biopsy when combined with a prostate cancer risk calculator?
Butoescu V; Ambroise J; Stainier A; Dekairelle AF; Gala JL; Tombal B
Prostate; 2014 Apr; 74(4):365-71. PubMed ID: 24265090
[TBL] [Abstract][Full Text] [Related]
2. Genetic predisposition to early recurrence in clinically localized prostate cancer.
Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
[TBL] [Abstract][Full Text] [Related]
3. Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.
Kader AK; Liss MA; Trottier G; Kim ST; Sun J; Zheng SL; Chadwick K; Lockwood G; Xu J; Fleshner NE
Urology; 2015 Jan; 85(1):165-70. PubMed ID: 25530379
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-finding protocol.
Pepe P; Aragona F
Can J Urol; 2013 Feb; 20(1):6620-4. PubMed ID: 23433132
[TBL] [Abstract][Full Text] [Related]
5. Utility of incorporating genetic variants for the early detection of prostate cancer.
Nam RK; Zhang WW; Trachtenberg J; Seth A; Klotz LH; Stanimirovic A; Punnen S; Venkateswaran V; Toi A; Loblaw DA; Sugar L; Siminovitch KA; Narod SA
Clin Cancer Res; 2009 Mar; 15(5):1787-93. PubMed ID: 19223501
[TBL] [Abstract][Full Text] [Related]
6. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
7. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
[TBL] [Abstract][Full Text] [Related]
8. Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy.
Nguyen CT; Yu C; Moussa A; Kattan MW; Jones JS
J Urol; 2010 Feb; 183(2):529-33. PubMed ID: 20006887
[TBL] [Abstract][Full Text] [Related]
9. Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms.
Morote J; Del Amo J; Borque A; Ars E; Hernández C; Herranz F; Arruza A; Llarena R; Planas J; Viso MJ; Palou J; Raventós CX; Tejedor D; Artieda M; Simón L; Martínez A; Rioja LA
J Urol; 2010 Aug; 184(2):506-11. PubMed ID: 20620409
[TBL] [Abstract][Full Text] [Related]
10. Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population.
Oh JJ; Byun SS; Lee SE; Hong SK; Jeong CW; Kim D; Kim HJ; Myung SC
Gene; 2014 Jan; 533(1):86-93. PubMed ID: 24120391
[TBL] [Abstract][Full Text] [Related]
11. Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.
Kader AK; Sun J; Reck BH; Newcombe PJ; Kim ST; Hsu FC; D'Agostino RB; Tao S; Zhang Z; Turner AR; Platek GT; Spraggs CF; Whittaker JC; Lane BR; Isaacs WB; Meyers DA; Bleecker ER; Torti FM; Trent JM; McConnell JD; Zheng SL; Condreay LD; Rittmaster RS; Xu J
Eur Urol; 2012 Dec; 62(6):953-61. PubMed ID: 22652152
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation on the effect of interobserver variability of digital rectal examination on the performance of the Rotterdam Prostate Cancer Risk Calculator.
Pereira-Azevedo N; Braga I; Verbeek JF; Osório L; Cavadas V; Fraga A; Carrasquinho E; Cardoso de Oliveira E; Nieboer D; Roobol MJ
Int J Urol; 2017 Dec; 24(12):826-832. PubMed ID: 28901582
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
14. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.
Trottier G; Roobol MJ; Lawrentschuk N; Boström PJ; Fernandes KA; Finelli A; Chadwick K; Evans A; van der Kwast TH; Toi A; Zlotta AR; Fleshner NE
BJU Int; 2011 Oct; 108(8 Pt 2):E237-44. PubMed ID: 21507190
[TBL] [Abstract][Full Text] [Related]
15. The presence of prostate cancer at biopsy is predicted by a number of genetic variants.
Kashyap A; Kluźniak W; Wokołorczyk D; Gołąb A; Sikorski A; Słojewski M; Gliniewicz B; Świtała J; Borkowski T; Borkowski A; Antczak A; Wojnar Ł; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała P; Piotrowski K; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Dębniak T; Górski B; Masojć B; van de Wetering T; Menkiszak J; Akbari MR; Lubiński J; Narod SA; Cybulski C;
Int J Cancer; 2014 Mar; 134(5):1139-46. PubMed ID: 24037955
[TBL] [Abstract][Full Text] [Related]
16. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
17. Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy.
Scattoni V; Raber M; Abdollah F; Roscigno M; Dehò F; Angiolilli D; Maccagnano C; Gallina A; Capitanio U; Freschi M; Doglioni C; Rigatti P; Montorsi F
Eur Urol; 2010 Jan; 57(1):1-8. PubMed ID: 19720449
[TBL] [Abstract][Full Text] [Related]
18. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
[TBL] [Abstract][Full Text] [Related]
19. The use of artificial neural network analysis to improve the predictive accuracy of prostate biopsy in the Japanese population.
Matsui Y; Utsunomiya N; Ichioka K; Ueda N; Yoshimura K; Terai A; Arai Y
Jpn J Clin Oncol; 2004 Oct; 34(10):602-7. PubMed ID: 15591458
[TBL] [Abstract][Full Text] [Related]
20. Development of improved nomogram for prediction of outcome of initial prostate biopsy using readily available clinical information.
Zaytoun OM; Kattan MW; Moussa AS; Li J; Yu C; Jones JS
Urology; 2011 Aug; 78(2):392-8. PubMed ID: 21705045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
